Skip to main content

Table 2 Medical history of patients with sustained, intermittent and non-PPI users

From: Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease

  Sustained PPI users Intermittent PPI users Non-PPI users p value
N 201 188 249  
Medicine history     
 Aspirin 149 (74.1%) 125 (66.5%) 170 (68.3%) 0.221
PPI     
 Pantoprazole 97 (48.2%) 96 (51.1%) 0.228
 Rabeprazole 9 (4.5%) 14 (7.4%) 0.399
 Lansoprazole 31 (15.4%) 18 (9.6%) 0.017
 Omeprazole 7 (3.5%) 18 (9.6%) 0.041
 Esomeprazole 4 (2.0%) 17 (9.0%) 0.007
 Two or more types 53 (26.4%) 25 (13.3%)  < 0.001
ACEI/ARB 140 (69.7%) 120 (63.8%) 152 (61.0%) 0.160
CCB 98 (48.8%) 78 (41.5%) 112 (45.0%) 0.354
β blocker 162 (80.6%) 133 (70.7%) 174 (69.9%) 0.022
Statin 192 (95.5%) 174 (92.6%) 223 (89.6%) 0.061
Warfarin 4 (2.0%) 1 (0.5%) 1 (0.4%) 0.175
  1. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; CCB, calcium channel blocker; PPI, proton pump inhibitor